<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03137563</url>
  </required_header>
  <id_info>
    <org_study_id>UF9839</org_study_id>
    <nct_id>NCT03137563</nct_id>
  </id_info>
  <brief_title>Acceptability of HPV-self Sampling</brief_title>
  <official_title>Evaluation of the Acceptability of HPV Self-sampling Among French Women Eligible for Cervical Cancer Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dépistages34 (Montpellier - France)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Adoc11 (Carcassonne - France)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maison médicale Paul Valéry - Union Languedoc Mutualité - (Montpellier -France)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aimed at evaluating the acceptability of HPV self-sampling among french women&#xD;
      eligible for cervical cancer screening (25 - 65 years old) in the region of Occitanie, in the&#xD;
      south of France. Acceptability will be evaluated using an anonymous questionnaire and the&#xD;
      main outcome of the study will be the response acceptability &quot; yes &quot; or &quot; no &quot; for HPV&#xD;
      self-sampling. Secondary outcome will be analysis of socioeconomic determinants for the&#xD;
      acceptability of HPV self-sampling.&#xD;
&#xD;
      These data will help to propose new strategies for cervical cancer screening in France,&#xD;
      particularly to taget non-attenting populations&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women will be recruted in 8 centers located in 2 departments , Aude and Herault (in the&#xD;
      Region of Occitanie in the south of France).The questionnaire will be proposed to the women&#xD;
      attending one of these eight centers by an investigator, who will verify the inclusion and&#xD;
      exclusion criteria. The same person will collect the filled questionnaire.&#xD;
&#xD;
      The questionnaire is anonymous and is composed of 15 questions evaluating the acceptability&#xD;
      of HPV self-sampling and socio-economic determinants.&#xD;
&#xD;
      These questionnaires will be collected and statistical analysis will be performed using&#xD;
      appropriate tools.&#xD;
&#xD;
      This study will bring informations on the acceptibility of HPV self sampling among french&#xD;
      women eligible for cervical cancer screening in 2 Departements of the South of France.&#xD;
      Self-sampling acceptability will be linked to socio-economic determinants.&#xD;
&#xD;
      These data will be important to propose and evaluate new strategies to improve screening&#xD;
      coverage, particularly of the context of the organized cervical cancer screening that will&#xD;
      take place in France in 2018.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Actual">July 30, 2019</completion_date>
  <primary_completion_date type="Actual">July 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>accept HPV self-sampling for cervical cancer</measure>
    <time_frame>1 day</time_frame>
    <description>Response &quot; Yes &quot; or &quot; No &quot; to the question &quot; would you accept HPV self-sampling for cervical cancer screening ?</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Socioeconomic determinants of the response</measure>
    <time_frame>1 day</time_frame>
    <description>Socioeconomic determinants of the response &quot; yes &quot; or &quot; no &quot; to the question &quot; would you accept HPV self-sampling for cervical cancer screening ?</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">356</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Women eligible for cervical cancer screening</arm_group_label>
    <description>French women aged 25 to 65 years living in the Department of Hérault or Aude (France), attending one of the 8 centers where the questionnaire will be distributed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire</intervention_name>
    <description>The questionnaire will be distributed and collected by the same investigator in one of the eight centers involved in the study. The investigator will verify the inclusion criteria and the absence of exclusion criteria.</description>
    <arm_group_label>Women eligible for cervical cancer screening</arm_group_label>
    <other_name>Distribution of an anonymous questionnaire</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women attending 8 centers of the Departments of Hearault and Aude : social medical cares,&#xD;
        Department of gynecology in the hospitals of Montpellier and Carcassonne ; mid-wifes&#xD;
        consultations.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women 25-65 years old&#xD;
&#xD;
          -  Living in the Aude or Herault departments&#xD;
&#xD;
          -  Informed patient Exclusion criteria&#xD;
&#xD;
          -  Virgins&#xD;
&#xD;
          -  Previous hysterectomy&#xD;
&#xD;
          -  Present or previous cervical pathology&#xD;
&#xD;
          -  Patient under guardianship or tutorship&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie BOULLE, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Bertucci M, Bonnet E, Satger L, Kreiche A, Chappert JL, Loy-Morel S, Segondy M, Daurès JP, Boulle N. Acceptability of vaginal self-sampling with high-risk human papillomavirus testing for cervical cancer screening: a French questionnaire-based study. Women Health. 2021 Jan;61(1):83-94. doi: 10.1080/03630242.2020.1831683. Epub 2020 Oct 26.</citation>
    <PMID>33106125</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Women</keyword>
  <keyword>25-65 years</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

